Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QLS-1128
- Development stage
- Phase 3
- Lead developer
- Qilu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
QLS-1128 is an orally available small molecule antiviral drug developed by Qilu Pharmaceutical. It acts as a selective inhibitor of the SARS-CoV-2 3C-like protease (3CLpro), also known as the main protease, which is essential for viral replication. The drug is being investigated primarily for the treatment of COVID-19 and has reached Phase 3 clinical trials in symptomatic patients with mild to moderate disease. Its mechanism targets a key enzyme required for coronavirus polyprotein processing, thereby inhibiting viral replication[1][2][7].
02
Targets
Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on QLS-1128.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLS-1128.